Ionis plans to initiate a Phase III trial for ION582 in the first half of 2025, positioning it just behind Ultragenyx in the race to bring a treatment to market for the rare neurologic condition.
Ionis Pharmaceuticals, Inc. is looking to initiate a Phase III trial for ION582 as quickly as possible based on positive data announced on 22 July from the Phase I/II open-label HALOS study in people with the rare neurological condition Angelman syndrome (AS).
“Our top priority is to gain alignment with the FDA rapidly and to move ION582 into Phase III development as...
Create an account to read this article
Already a subscriber?
The privately owned biotech said it would pause its Phase I/II study of CAP-002 in STXBP1-related disorders after the first patient in the study died.
Charl van Zyl tells Scrip that pipeline is the priority as the company discontinues commercial operations in 27 markets.
Phase IIa data for Dianthus’ complement C1s inhibitor claseprubart in myasthenia gravis showed strong efficacy, less frequent dosing and no risk of infections relative to a growing list of competing drugs.
Phase IIa data testing RAP-219 could position it as best-in-class for focal onset seizures.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.
Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.
